[Screening for opportunistic infections and vaccination before introduction of biologic therapy].
Patients on anti-TNFalpha medications carry a higher risk for developing opportunistic infections. In order to introduce anti-TNFalpha therapy, screening for hepatitis viruses B and C, HIV, EBV, HPV, TBC, bacterial, fungal and parasitic infections should be performed. Screening involves patient's history of earlier infectious diseases, vaccinations and traveling to parts of the world with endemic diseases. Clinical examination should be supplemented with stomatologic and gynecologic exams. Laboratory results include leukogram, transaminases, C-reactive protein, urine analysis, hepatitis B, C, HIV and EBV serology. Varicella zoster virus serology depends on past medical history. If the patient has traveled to tropical areas, both stool analysis and strongiloidiasis serology should be performed. Other mandatory examinations include chest radiography, PPD and TBC serology using interferon gamma release test (IGRA). If suspecting intra-abdominal abscess, magnetic resonance of the abdomen is recommended. In case of abscess, CMV or Clostridium difficile colitis anti-TNF-alpha therapy is contraindicated. Live vaccine application is contraindicated in patients receiving anti-TNFalpha therapy. All seronegative patients should be vaccinated against hepatitis B virus. Seasonal flu vaccination is recommended to be applicated yearly and pneumococcal polysaccharide vaccine once in every five years. Based on the past medical history and serologic results, patients are vaccinated against VZV with extra precaution. Human papilloma virus vaccination is performed in a group of women under 23 years of age, after gathering cervical smear sample analysis.
Zavod za gastroenterologiju, Klinika za internu medicinu, Klinicki bolnicki centar Rijeka, Medicinski fakultet Sveucilista u Rijeci, Rijeka. bsincic@gmail.com
Brankica Mijandrusić
BM
Sincić
Klinika za infektivne bolesti Dr Fran Mihaljević, Medicinski fakultet, Sveuciliste u Zagrebu, Zagreb, Hrvatska.
Adriana
A
Vince
D001691:Biological Therapy / Q000379:methods*; D005260:Female; D005762:Gastroenterology / Q000592:standards; D006509:Hepatitis B / Q000517:prevention & control; D006526:Hepatitis C / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy; D008297:Male; D008403:Mass Screening / Q000379:methods*; D009894:Opportunistic Infections / Q000139:chemically induced / Q000175:diagnosis* / Q000517:prevention & control*; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians'; D014611:Vaccination / Q000592:standards*; D014777:Virus Diseases / Q000175:diagnosis
D007166:Immunosuppressive Agents